Involvement of DPP IV/CD26 in cutaneous wound healing process in mice

Wound Repair and Regeneration

Volumn 25, Issue 1, 2017, Pages 25-40

  Baticic Pucar, Lara ^a   Pernjak Pugel, Ester ^a   Detel, Dijana ^a   Varljen, Jadranka ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN; DERMATOLOGICAL AGENT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONNECTIVE TISSUE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; MACROPHAGE; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN INJURY; T LYMPHOCYTE; WOUND CLOSURE; WOUND HEALING; WOUND TISSUE; ANIMAL; BIOSYNTHESIS; DEFICIENCY; DRUG EFFECTS; INJURY; METABOLISM; PHYSIOLOGY; SKIN ULCER;

ANIMALS; DERMATOLOGIC AGENTS; DIPEPTIDYL PEPTIDASE 4; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; SKIN ULCER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING; WOUNDS AND INJURIES;

EID: 85012247979     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12498     Document Type: Article

References (39)

1. Kim DJ, Mustoe T, Clark RA. Cutaneous wound healing in aging small mammals: a systematic review. Wound Repair Regen 2015; 23: 318-39.
2. Waumans Y, Baerts L, Kehoe K, Lambeir AM, De Meester I. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front Immunol 2015; 6: 387
3. Singh AK, Singh R. Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences. Expert Rev Clin Pharmacol 2016; 9: 605-16.
4. Marfella R, Sasso FC, Rizzo MR, Paolisso P, Barbieri M, Padovano V, et al. Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. Exp Diabetes Res 2012; 2012: 892706.
5. Schurmann C, Linke A, Engelmann-Pilger K, Steinmetz C, Mark M, Pfeilschifter J, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther 2012;342 (1):71-80.
6. Thielitz A, Vetter RW, Schultze B, Wrenger S, Simeoni L, Ansorge S, et al. Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. J Invest Dermatol 2008; 128: 855-66.
7. Sinagra T, Merlo S, Spampinato SF, Pasquale RD, Sortino MA. High mobility group box 1 contributes to wound healing induced by inhibition of dipeptidylpeptidase 4 in cultured keratinocytes. Front Pharmacol 2015; 6: 126
8. Van de Velde S, Hogan MF, Montminy M. mTOR links incretin signaling to HIF induction in pancreatic beta cells. Proc Natl Acad Sci USA 2011; 108: 16876-82.
9. Bodnar RJ, Yates CC, Wells A. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res 2006; 98: 617-25.
10. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97: 6874-9.
11. (−/−) mice due to a decrease in TGF-beta1 and myofibroblast differentiation. EMBO J 2005; 24: 3400-10.
12. Straino S, Di Carlo A, Mangoni A, De Mori R, Guerra L, Maurelli R, et al. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol 2008; 128: 1545-53.
13. Villavedra M, Carol H, Hjulstrom M, Holmgren J, Czerkinsky C. “PERFEXT”: a direct method for quantitative assessment of cytokine production in vivo at the local level. Res Immunol 1997; 148: 257-66.
14. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
15. Kreisel W, Heussner R, Volk B, Buchsel R, Reutter W, Gerok W. Identification of the 110000 Mr glycoprotein isolated from rat liver plasma membrane as dipeptidylaminopeptidase IV. FEBS Lett 1982; 147: 85-8.
16. Martin P, Nunan R. Cellular and molecular mechanisms of repair in acute and chronic wound healing. Br J Dermatol 2015; 173: 370-8.
17. Leoni G, Neumann PA, Sumagin R, Denning TL, Nusrat A. Wound repair: role of immune-epithelial interactions. Mucosal Immunol 2015; 8: 959-68.
18. Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 2004; 23: 317-29.
19. Rinkevich Y, Walmsley GG, Hu MS, Maan ZN, Newman AM, Drukker M, et al. Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science 2015; 348: aaa2151.
20. Bodnar RJ. Chemokine regulation of angiogenesis during wound healing. Adv Wound Care (New Rochelle) 2015; 4: 641-50.
21. Johnson KE, Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle) 2014; 3: 647-61.
22. Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, et al. Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. Kidney Int 2015; 88: 479-89.
23. Hoang MV, Nagy JA, Senger DR. Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. Blood 2011; 117: 1751-60.
24. Saboo A, Rathnayake A, Vangaveti VN, Malabu UH. Wound healing effects of dipeptidyl peptidase-4 inhibitors: an emerging concept in management of diabetic foot ulcer-A review. Diabetes Metab Syndr 2016; 10: 113-9.
25. Xiao-Yun X, Zhao-Hui M, Ke C, Hong-Hui H, Yan-Hong X. Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Med Sci Monit 2011; 17: BR35-BR41.
26. Bulut K, Meier JJ, Ansorge N, Felderbauer P, Schmitz F, Hoffmann P, et al. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF–beta-mediated effect. Regul Pept 2004; 121: 137-43.
27. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-64.
28. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33: 1607−9.
29. Yates-Binder CC, Rodgers M, Jaynes J, Wells A, Bodnar RJ, Turner T. An IP-10 (CXCL10)-derived peptide inhibits angiogenesis. PLoS One 2012; 7: e40812
30. Ragab D, Laird M, Duffy D, Casrouge A, Mamdouh R, Abass A, et al. CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients. Cytokine 2013;63 (2):105-112.
31. Luster AD, Cardiff RD, MacLean JA, Crowe K, Granstein RD. Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proc Assoc Am Phys 1998; 110: 183-96.
32. Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011; 121: 308-17.
33. Nissinen LM, Kahari VM. Collagen turnover in wound repair—a macrophage connection. J Invest Dermatol 2015; 135: 2350-2.
34. Frank S, Kampfer H, Wetzler C, Stallmeyer B, Pfeilschifter J. Large induction of the chemotactic cytokine RANTES during cutaneous wound repair: a regulatory role for nitric oxide in keratinocyte-derived RANTES expression. Biochem J 2000; 347: 265-73.
35. Brancato SK, Albina JE. Wound macrophages as key regulators of repair: origin, phenotype, and function. Am J Pathol 2011; 178: 19-25.
36. Hsu CW, Poche RA, Saik JE, Ali S, Wang S, Yosef N, et al. Improved angiogenesis in response to localized delivery of macrophage-recruiting molecules. PLoS One 2015; 10: e0131643.
37. Detel D, Pugel EP, Pucar LB, Buljevic S, Varljen J. Development and resolution of colitis in mice with target deletion of dipeptidyl peptidase IV. Exp Physiol 2012; 97: 486-96.
38. Baticic L, Detel D, Kucic N, Buljevic S, Pugel EP, Varljen J. Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice. J Cell Biochem 2011; 112: 3322-33.
39. Varljen J, Sincic BM, Baticic L, Varljen N, Detel D, Lekic A. Clinical relevance of the serum dipeptidyl peptidase IV (DPP IV/CD26) activity in adult patients with Crohn's disease and ulcerative colitis. Croat Chem Acta 2005; 78: 427-32.